N,N-Dimethyltryptamine

Phase 2Small molecule

AAlgernon Pharmaceuticals

N,N-Dimethyltryptamine is one of 47 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

MDDRecruiting

PropofolRecruiting

StrokePhase 1

Active, not recruiting

MDDPhase 2

Recruiting

PropofolPreclinical

Recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

N,N-Dimethyltryptamine

AAlgernon Pharmaceuticals

Phase 2

9 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Repatha

Proamatine

Zantac 150

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

MDD

NCT07562191

Q1 2029

N/ARecruiting

Propofol

NCT06927076

Q3 2029

Phase 1Not yet recruiting

Study completion

NCT07693257

Clinical

Trials by Indication[1]

Acute2 trials

Acute Dose-dependent Effects of DMT in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT05384678·24 enrolled

Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT05695495·36 enrolled

Adult2 trials

Safety and Tolerability of DMT in Healthy Adults

Completed·UUniversidade Federal do Rio Grande do Norte·Phase 1·NCT05901012·25 enrolled

Clinical Study of DMT in Healthy Adults

Completed·BBiomind Labs Inc.·Phase 1·NCT05573568·27 enrolled

Depression1 trial

Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

Completed·UUniversidade Federal do Rio Grande do Norte·Phase 2·NCT06094907·14 enrolled

Propofol1 trial

Antidepressant Response of DMT Masked With Propofol

Recruiting·UUniversity Hospital, Basel, Switzerland·N/A·NCT06927076·112 enrolled

MDD1 trial

Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial of Inhaled N,N-Dimethyltryptamine (DMT) for Major Depressive Disorder

Recruiting·UUniversidade Federal do Rio Grande do Norte·Phase 2·NCT07562191·140 enrolled

1 more indication

Unspecified2 trials

Single and Repeat Doses of DMT in Healthy Subjects

Active, not recruiting·AAlgernon Pharmaceuticals·Phase 1·NCT05559931·60 enrolled

Neural Effects of Continuous Intravenous Infusion of N,N-dimethyltryptamine (DMT)

Not yet recruiting·JJon Dean·Phase 1·NCT07693257·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for N,N-Dimethyltryptamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N,N-Dimethyltryptamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N,N-Dimethyltryptamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Algernon Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlgernon Pharmaceuticals

N,N-Dimethyltryptamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Q3 2029

Trials by Indication[1]

Acute2 trials

Adult2 trials

Depression1 trial

Propofol1 trial

MDD1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News